Julian Harrison
Stock Analyst at BTIG
(3.40)
# 1,057
Out of 4,412 analysts
24
Total ratings
42.11%
Success rate
8.01%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Initiates: Buy | $21 | $9.12 | +130.26% | 1 | Apr 12, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $50 | $8.43 | +493.12% | 3 | Mar 27, 2024 | |
| ANAB AnaptysBio | Initiates: Buy | $55 | $21.00 | +161.90% | 1 | Feb 26, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Neutral | n/a | $1.20 | - | 3 | Jan 11, 2024 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $32 | $33.56 | -4.65% | 1 | Dec 20, 2023 | |
| APGE Apogee Therapeutics | Initiates: Buy | $43 | $47.13 | -8.76% | 1 | Dec 20, 2023 | |
| AKBA Akebia Therapeutics | Assumes: Buy | $4 | $1.34 | +198.51% | 1 | Nov 29, 2023 | |
| MTNB Matinas BioPharma Holdings | Reinstates: Buy | $3 | $0.18 | +1,576.91% | 1 | Oct 11, 2023 | |
| MORF Morphic Holding | Downgrades: Neutral | n/a | $28.07 | - | 2 | Sep 25, 2023 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $41 | $25.15 | +63.02% | 1 | Jul 3, 2023 | |
| VRDN Viridian Therapeutics | Initiates: Buy | $46 | $12.88 | +257.14% | 1 | Jun 14, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Buy | $36 | $42.49 | -15.27% | 1 | Mar 9, 2023 | |
| KROS Keros Therapeutics | Maintains: Buy | $95 → $105 | $57.86 | +81.47% | 2 | Dec 13, 2022 | |
| AVTE Aerovate Therapeutics | Upgrades: Buy | $27 | $21.75 | +24.14% | 3 | Dec 6, 2022 | |
| LQDA Liquidia | Maintains: Buy | $14 → $17 | $12.53 | +35.67% | 1 | Jul 20, 2022 | |
| UTHR United Therapeutics | Initiates: Neutral | n/a | $233.85 | - | 1 | Feb 11, 2022 |
Theravance Biopharma
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $9.12
Upside: +130.26%
Outlook Therapeutics
Mar 27, 2024
Upgrades: Buy
Price Target: $50
Current: $8.43
Upside: +493.12%
AnaptysBio
Feb 26, 2024
Initiates: Buy
Price Target: $55
Current: $21.00
Upside: +161.90%
Aclaris Therapeutics
Jan 11, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.20
Upside: -
Spyre Therapeutics
Dec 20, 2023
Initiates: Buy
Price Target: $32
Current: $33.56
Upside: -4.65%
Apogee Therapeutics
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $47.13
Upside: -8.76%
Akebia Therapeutics
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $1.34
Upside: +198.51%
Matinas BioPharma Holdings
Oct 11, 2023
Reinstates: Buy
Price Target: $3
Current: $0.18
Upside: +1,576.91%
Morphic Holding
Sep 25, 2023
Downgrades: Neutral
Price Target: n/a
Current: $28.07
Upside: -
Protagonist Therapeutics
Jul 3, 2023
Reiterates: Buy
Price Target: $41
Current: $25.15
Upside: +63.02%
Viridian Therapeutics
Jun 14, 2023
Initiates: Buy
Price Target: $46
Current: $12.88
Upside: +257.14%
MoonLake Immunotherapeutics
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $42.49
Upside: -15.27%
Keros Therapeutics
Dec 13, 2022
Maintains: Buy
Price Target: $95 → $105
Current: $57.86
Upside: +81.47%
Aerovate Therapeutics
Dec 6, 2022
Upgrades: Buy
Price Target: $27
Current: $21.75
Upside: +24.14%
Liquidia
Jul 20, 2022
Maintains: Buy
Price Target: $14 → $17
Current: $12.53
Upside: +35.67%
United Therapeutics
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $233.85
Upside: -